Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06479863 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis

StatusRecruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site contacts updated at 2 of 2 sitesv4
  2. Re-verified, no change to tracked fieldsv3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 2
    • Start date changed from estimate of Jul 15, 2024 to Aug 8, 2024
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To evaluate the efficacy of Pozelimab/Cemdisiran combination therapy in patients with sIBM
Trial Details
NCT Number NCT06479863
Lead Sponsor Austin Neuromuscular Center
Collaborators: Regeneron Pharmaceuticals
Conditions
(from sponsor)		 Sporadic Inclusion Body Myositis (sIBM), Idiopathic Inflammatory Myopathies
Related terms Myositis, Myositis, Inclusion Body
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov